Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Urologix' Targis

This article was originally published in The Gray Sheet

Executive Summary

Production of the microwave-based system for benign prostatic hyperplasia begins at Plexus Corp. under a two-year manufacturing agreement announced Oct. 24. Initial deliveries from Plexus are slated for December. Quality system deficiencies have hampered production at Colorado MEDtech under a previous arrangement (1"The Gray Sheet" Aug. 13, 2001, p. 13). Minneapolis-based Urologix continues to develop redundant, in-house manufacturing facilities for the device, approved by FDA in 1997, and expects completion by mid-2002

You may also be interested in...



Urologix March Stock Price Gain Propelled By BPH Systems, Disposables

Increased market penetration and improved reimbursement rates for Urologix, Inc.'s Targis Cooled ThermoTherapy system for treatment of benign prostatic hyperplasia (BPH) translated into a nearly 30% stock price gain in March. The issue advanced $4.17 to close at $18.17 for the month

Urologix March Stock Price Gain Propelled By BPH Systems, Disposables

Increased market penetration and improved reimbursement rates for Urologix, Inc.'s Targis Cooled ThermoTherapy system for treatment of benign prostatic hyperplasia (BPH) translated into a nearly 30% stock price gain in March. The issue advanced $4.17 to close at $18.17 for the month

Urologix Targis TUMT Production To Resume By Year-End

Urologix expects to resume production of its Targis transurethral microwave thermotherapy (TUMT) system for benign prostatic hyperplasia by year-end after manufacturing partner Colorado MEDtech corrects several quality system deficiencies.

Related Content

UsernamePublicRestriction

Register

MT015627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel